Evidence map›Paper›PMID 33669134›Full record

ReviewBiomedicines2021

Apoceruloplasmin: Abundance, Detection, Formation, and Metabolism.

Maria C Linder

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Monitoring of Copper in Wilson Disease.Diagnostics (Basel, Switzerland) · 2023
    Review
  10. Review
  11. Secretion and uptake of copper via a small copper carrier in blood fluid.Metallomics : integrated biometal science · 2022
    Article
  12. Article
  13. Article
  14. Ceruloplasmin as a source of Cu for a fungal pathogen.Journal of inorganic biochemistry · 2021
    Article
  15. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Maria C LinderDepartment of Chemistry and Biochemistry, California State University, Fullerton, CA 91831, USA.ORCID 0000-0003-3937-9268
California State University, Fullerton · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceruloplasmin, the main copper-binding protein in blood and some other fluids, is well known for its copper-dependent enzymatic functions and as a source of copper for cells. What is generally unknown or ignored is that, at least in the case of blood plasma and serum, about half of ceruloplasmin is in the apo (copper-free) form. This has led to some misconceptions about the amounts and variations of other copper-binding proteins and so-called "free copper" in the blood that might be indicators of disease states. What is known about the levels, sources, and metabolism of apo versus holo ceruloplasmin and the problems associated with measurements of the two forms is reviewed here.

Indexed as

apoceruloplasminceruloplasminceruloplasmin secretion and turnovernon-ceruloplasmin copper

Identifiers

PMID33669134
PMCPMC7996503
OpenAlexW3130162938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.